Rosa Mònica, Bech-Serra Joan Josep, Canals Francesc, Zajac Jean Marie, Talmont Franck, Arsequell Gemma, Valencia Gregorio
†Unit of Glycoconjugate Chemistry, Department of Biomedicinal Chemistry, Institute of Advanced Chemistry of Catalonia, Spanish National Research Council (IQAC-CSIC), 08034 Barcelona, Spain.
‡Proteomics Laboratory, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, ProteoRed ISCIII, 08035 Barcelona, Spain.
J Proteome Res. 2015 Aug 7;14(8):3162-73. doi: 10.1021/acs.jproteome.5b00104. Epub 2015 Jul 7.
Human μ-opioid receptor (hMOR) is a class-A G-protein-coupled receptor (GPCR), a prime therapeutic target for the management of moderate and severe pain. A chimeric form of the receptor has been cocrystallized with an opioid antagonist and resolved by X-ray diffraction; however, further direct structural analysis is still required to identify the active form of the receptor to facilitate the rational design of hMOR-selective agonist and antagonists with therapeutic potential. Toward this goal and in spite of the intrinsic difficulties posed by the highly hydrophobic transmembrane motives of hMOR, we have comprehensively characterized by mass spectrometry (MS) analysis the primary sequence of the functional hMOR. Recombinant hMOR was overexpressed as a C-terminal c-myc and 6-his tagged protein using an optimized expression procedure in Pichia pastoris cells. After membrane solubilization and metal-affinity chromatography purification, a procedure was devised to enhance the concentration of the receptor. Subsequent combinations of in-solution and in-gel digestions using either trypsin, chymotrypsin, or proteinase K, followed by matrix-assisted laser desorption ionization time-of-flight MS or nanoliquid chromatography coupled with tandem MS analyses afforded an overall sequence coverage of up to >80%, a level of description first attained for an opioid receptor and one of the six such high-coverage MS-based analyses of any GPCR.
人μ-阿片受体(hMOR)是一种A类G蛋白偶联受体(GPCR),是治疗中度和重度疼痛的主要治疗靶点。该受体的一种嵌合形式已与阿片类拮抗剂共结晶,并通过X射线衍射解析;然而,仍需要进一步的直接结构分析来确定受体的活性形式,以促进具有治疗潜力的hMOR选择性激动剂和拮抗剂的合理设计。为了实现这一目标,尽管hMOR高度疏水的跨膜结构域带来了内在困难,我们还是通过质谱(MS)分析全面表征了功能性hMOR的一级序列。使用优化的表达程序在毕赤酵母细胞中,将重组hMOR作为C端带有c-myc和6-组氨酸标签的蛋白进行过表达。在膜溶解和金属亲和层析纯化后,设计了一种提高受体浓度的方法。随后,使用胰蛋白酶﹑胰凝乳蛋白酶或蛋白酶K进行溶液内和凝胶内消化,再结合基质辅助激光解吸电离飞行时间质谱或纳升液相色谱与串联质谱分析,总体序列覆盖率高达80%以上,这是阿片受体首次达到的描述水平,也是任何GPCR基于质谱的六项此类高覆盖率分析之一。